EGFR and glioblastoma: MiR-486-3p inhibits the proliferation, migration, and invasion of retinoblastoma, inhibits the proliferation and metastasis of cervical cancer, targets FGFR4 and EGFR to mediate drug resistance in hepatocellular carcinoma, and reverses the malignant phenotype of GBM cells [53–55].